ArticleBMC endocrine disorders2026
Age-specific TSH reference limits and early levothyroxine effects in postmenopausal women with subclinical hypothyroidism: a prospective cohort study in Vietnam.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSubclinical hypothyroidism (SCH) in postmenopausal women is challenging to diagnose due to age-related shifts in thyroid-stimulating hormone (TSH) and a lack of population-specific reference limits. Evidence on levothyroxine responsiveness in this group is also limited. This study aimed to establish age-specific TSH reference limits in postmenopausal women and to evaluate the six-month effects of low-dose levothyroxine on thyroid-related quality of life and thyroid function.
methodsAge-specific TSH reference limits were derived from 754 euthyroid postmenopausal women. A separate cohort of 27 women with subclinical hypothyroidism was prospectively followed for six months during levothyroxine therapy initiated with conservative dosing and adjusted according to TSH response. Thyroid function and ThyPRO scores were assessed at baseline, 3 months, and 6 months.
resultsThe 97·5th percentile upper TSH limits were 3.43 mU/L (ages 50–64) and 3.57 mU/L (≥65 years), both lower than values reported in international cohorts. Levothyroxine therapy produced a clinically meaningful 6.5-point improvement in ThyPRO scores. Median TSH decreased from 7.30 mU/L (IQR 5.56–12.21) at baseline to 2.14 mU/L (IQR 1.43–2.92) at 6 months, with modest increases in free thyroxine. Anthropometric and cardiometabolic parameters did not show meaningful changes over the 6-month follow-up.
conclusionsPostmenopausal women in this population exhibited lower age-specific TSH limits than those reported internationally, supporting a ≥ 4.5 mU/L diagnostic threshold for subclinical hypothyroidism. Low-dose levothyroxine improved thyroid-related quality of life without short-term metabolic effects. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.